Physician profile
Paul A Trautmann
NPI 1942385091
$1,243.58
in general payments reported to CMS, 2019-2025
23 companies · $14.44 in 2025
The $14.44 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $142 · 2020: $247 · 2021: $110 · 2022: $362 · 2023: $203 · 2024: $165 · 2025: $14.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $382.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $184.59 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $174.63 | 2021-2022 | |
| Abbott Laboratories | $133.26 | 2023 | Proclaim |
| Pacira Pharmaceuticals Incorporated | $124.99 | 2022 | |
| Roche Diagnostics Corporation | $90.04 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $82.00 | 2019-2024 | Vaxneuvance, Gardasil 9, Vaqta |
| Abbvie INC. | $65.46 | 2019-2021 | |
| Corium, LLC | $53.07 | 2023 | Azstarys |
| Sanofi Pasteur INC. | $48.07 | 2022 | |
| Biogen, INC. | $44.24 | 2024 | Zurzuvae |
| Agile Therapeutics, INC. | $31.36 | 2021 | |
| Pfizer INC. | $30.02 | 2019-2021 | |
| Aspira Women'S Health INC | $27.13 | 2024 | Ova1 |
| Bayer Healthcare Pharmaceuticals INC. | $23.97 | 2020 | |
| Evofem Biosciences, INC. | $17.99 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $16.92 | 2023 | Arista Ah Flexitip |
| Verrica Pharmaceuticals INC. | $15.51 | 2024 | Ycanth |
| Cumberland Pharmaceuticals, INC. | $14.93 | 2024 | Kristalose |
| Glaxosmithkline, LLC. | $14.44 | 2025 | Bexsero, Rotarix, Pediarix |
| Duchesnay USA Incorporated | $14.05 | 2019 | |
| Shield Therapeutics INC | $13.37 | 2024 | |
| Organon LLC | $12.15 | 2024 | |
| Millicent US INC | $11.39 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Trautmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.